Highlights From the 14th Annual Congress of EAHAD
Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults With Severe or Moderate-Severe Hemophilia B: Two Year Data From a Phase 2b Trial
Annette von Drygalski, MD, PharmD1, Adam Giermasz, MD, PhD2, Giancarlo Castaman, MD3, Nigel S. Key, MBChB4, Susan U. Lattimore, RN5, Frank W.G. Leebeek, MD6, Wolfgang A. Miesbach, MD, PhD7,
Michael Recht, MD, PhD5, Esteban Gomez, MD8, Robert Gut, MD, PhD9, and Steven W. Pipe, MD10
1University of California San Diego, La Jolla, CA, USA
2University of California Davis, Sacramento, CA, USA
3Azienda Ospedaliera Universitaria Careggi, Florence, Italy
4University of North Carolina, Chapel Hill, USA
5Oregon Health and Science University, Portland, USA
6Erasmus University Medical Center, Rotterdam, The Netherlands
7University Hospital Frankfurt, Germany
8Phoenix Children's Hospital, Phoenix, USA
9uniQure Inc, Lexington, MA, USA
10University of Michigan, Ann Arbor, MI, USA
Annette von Drygalski, MD, PharmD1, Adam Giermasz, MD, PhD2, Giancarlo Castaman, MD3, Nigel S. Key, MBChB4, Susan U. Lattimore, RN5, Frank W.G. Leebeek, MD6, Wolfgang A. Miesbach, MD, PhD7, Michael Recht, MD, PhD5, Esteban Gomez, MD8, Robert Gut, MD, PhD9, and Steven W. Pipe, MD10
1University of California San Diego, La Jolla, CA, USA
2University of California Davis, Sacramento, CA, USA
3Azienda Ospedaliera Universitaria Careggi, Florence, Italy
4University of North Carolina, Chapel Hill, USA
5Oregon Health and Science University, Portland, USA
6Erasmus University Medical Center, Rotterdam, The Netherlands
7University Hospital Frankfurt, Germany
8Phoenix Children's Hospital, Phoenix, USA
9uniQure Inc, Lexington, MA, USA
10University of Michigan, Ann Arbor, MI, USA



